36
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Integrated Analysis Reveals That miR-193b, miR-671, and TREM-1 Correlate With a Good Response to Treatment of Human Localized Cutaneous Leishmaniasis Caused by Leishmania braziliensis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Localized cutaneous leishmaniasis (LCL) is a chronic disease characterized by ulcerated skin lesion(s) and uncontrolled inflammation. The mechanisms underlying the pathogenesis of LCL are not completely understood, and little is known about posttranscriptional regulation during LCL. MicroRNAs (miRNAs) are non-coding small RNAs that regulate gene expression and can be implicated in the pathogenesis of LCL. We investigated the involvement of miRNAs and their targets genes in human LCL using publicly available transcriptome data sets followed by ex vivo validation. Initial analysis highlighted that miRNA expression is altered during LCL, as patients clustered separately from controls. Joint analysis identified eight high confidence miRNAs that had altered expression (−1.5 ≤ fold change ≥ 1.5; p < 0.05) between cutaneous ulcers and uninfected skin. We found that the expression of miR-193b and miR-671 are greatly associated with their target genes, CD40 and TNFR, indicating the important role of these miRNAs in the expression of genes related to the inflammatory response observed in LCL. In addition, network analysis revealed that miR-193b, miR-671, and TREM1 correlate only in patients who show faster wound healing (up to 59 days) and not in patients who require longer cure times (more than 60 days). Given that these miRNAs are associated with control of inflammation and healing time, our findings reveal that they might influence the pathogenesis and prognosis of LCL.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.

          Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer

            Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as oncogenes or tumor suppressor genes. This review presents the state of the art on the role of miRNAs in the diagnosis, prognosis, and therapy of BC. Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335), and prediction of therapeutic outcomes (i.e., miR-30c, miR-187, and miR-339-5p) and have important roles in the control of BC hallmark functions such as invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs are of interest as new, easily accessible, affordable, non-invasive tools for the personalized management of patients with BC because they are circulating in body fluids (e.g., miR-155 and miR-210). In particular, circulating multiple miRNA profiles are showing better diagnostic and prognostic performance as well as better sensitivity than individual miRNAs in BC. New miRNA-based drugs are also promising therapy for BC (e.g., miR-9, miR-21, miR34a, miR145, and miR150), and other miRNAs are showing a fundamental role in modulation of the response to other non-miRNA treatments, being able to increase their efficacy (e.g., miR-21, miR34a, miR195, miR200c, and miR203 in combination with chemotherapy).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Leishmaniasis: complexity at the host-pathogen interface.

              Leishmania is a genus of protozoan parasites that are transmitted by the bite of phlebotomine sandflies and give rise to a range of diseases (collectively known as leishmaniases) that affect over 150 million people worldwide. Cellular immune mechanisms have a major role in the control of infections with all Leishmania spp. However, as discussed in this Review, recent evidence suggests that each host-pathogen combination evokes different solutions to the problems of parasite establishment, survival and persistence. Understanding the extent of this diversity will be increasingly important in ensuring the development of broadly applicable vaccines, drugs and immunotherapeutic interventions.
                Bookmark

                Author and article information

                Contributors
                URI : https://frontiersin.org/people/u/541235
                URI : https://frontiersin.org/people/u/506542
                URI : https://frontiersin.org/people/u/534820
                URI : https://frontiersin.org/people/u/131329
                URI : https://frontiersin.org/people/u/473779
                URI : https://frontiersin.org/people/u/484625
                URI : https://frontiersin.org/people/u/30513
                URI : https://frontiersin.org/people/u/466413
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                04 April 2018
                2018
                : 9
                : 640
                Affiliations
                [1] 1Oswaldo Cruz Foundation, Gonçalo Moniz Institute, FIOCRUZ , Salvador, Brazil
                [2] 2Federal University of Bahia , Salvador, Brazil
                [3] 3Laboratório de Anatomia Patológica , Feira de Santana, Brazil
                [4] 4Centre for Data and Knowledge Integration for Health (CIDACS), FIOCRUZ , Salvador, Brazil
                Author notes

                Edited by: José Roberto Mineo, Federal University of Uberlandia, Brazil

                Reviewed by: Hira Nakhasi, Center for Biologics Evaluation and Research (FDA), United States; Maryam Dadar, Razi Vaccine and Serum Research Institute, Iran

                *Correspondence: Natalia Machado Tavares, natalia.tavares@ 123456bahia.fiocruz.br

                Specialty section: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2018.00640
                5893808
                30705678
                ff01cf2d-2f19-45c0-93d7-bbd78cbdc540
                Copyright © 2018 Nunes, Silva, Ampuero, Noronha, Souza, Correia, Khouri, Boaventura, Barral, Ramos, Brodskyn, Oliveira and Tavares.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 11 December 2017
                : 14 March 2018
                Page count
                Figures: 4, Tables: 0, Equations: 0, References: 120, Pages: 13, Words: 9932
                Funding
                Funded by: Fundação de Amparo à Pesquisa do Estado da Bahia 10.13039/501100006181
                Award ID: 460/2015
                Categories
                Immunology
                Original Research

                Immunology
                leishmania braziliensis,microrna,skin,transcriptome,trem-1,human leishmaniasis
                Immunology
                leishmania braziliensis, microrna, skin, transcriptome, trem-1, human leishmaniasis

                Comments

                Comment on this article